Midkine activation of CD8+ T cells establishes a neuron–immune–cancer axis responsible for low-grade glioma growth by Guo, Xiaofan et al.
Washington University School of Medicine 
Digital Commons@Becker 
Open Access Publications 
2020 
Midkine activation of CD8+ T cells establishes a 
neuron–immune–cancer axis responsible for low-grade glioma 
growth 
Xiaofan Guo 
Yuan Pan 
Min Xiong 
Shilpa Sanapala 
Corina Anastasaki 
See next page for additional authors 
Follow this and additional works at: https://digitalcommons.wustl.edu/open_access_pubs 
Authors 
Xiaofan Guo, Yuan Pan, Min Xiong, Shilpa Sanapala, Corina Anastasaki, Olivia Cobb, Sonika Dahiya, and 
David H. Gutmann 
ARTICLE
Midkine activation of CD8+ T cells establishes
a neuron–immune–cancer axis responsible
for low-grade glioma growth
Xiaofan Guo1, Yuan Pan 1, Min Xiong1, Shilpa Sanapala1, Corina Anastasaki1, Olivia Cobb1, Sonika Dahiya 2 &
David H. Gutmann 1✉
Brain tumors (gliomas) are heterogeneous cellular ecosystems, where non-neoplastic
monocytic cells have emerged as key regulators of tumor maintenance and progression.
However, relative to macrophages/microglia, comparatively less is known about the roles of
neurons and T cells in glioma pathobiology. Herein, we leverage genetically engineered
mouse models and human biospecimens to define the axis in which neurons, T cells, and
microglia interact to govern Neurofibromatosis-1 (NF1) low-grade glioma (LGG) growth. NF1-
mutant human and mouse brain neurons elaborate midkine to activate naïve CD8+ T cells to
produce Ccl4, which induces microglia to produce a key LGG growth factor (Ccl5) critical for
LGG stem cell survival. Importantly, increased CCL5 expression is associated with reduced
survival in patients with LGG. The elucidation of the critical intercellular dependencies that
constitute the LGG neuroimmune axis provides insights into the role of neurons and immune
cells in controlling glioma growth, relevant to future therapeutic targeting.
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Numerous studies in malignant solid tumors have high-lighted the importance of non-neoplastic stromal cells,particularly cancer-associated fibroblasts, in tumor for-
mation, growth, and progression1,2. However, in nervous system
cancers, fibroblasts are not part of the tumor microenvironment,
suggesting that other non-neoplastic cells, including neurons and
immune cells (T cells, microglia, and macrophages), could serve
this critical function. In this respect, both brain and nerve sheath
tumors are characterized by the presence of neurons and infil-
trating immune cells3,4, which could each provide cancer cell
support.
These cellular interactions have been more extensively studied
in malignant brain tumors (e.g. glioblastoma and diffuse midline
glioma), where cancer cells attract resident microglia and per-
ipheral macrophages through the elaboration of chemokines,
which in turn produce growth factors that promote tumor growth
and progression5. Similarly, neurons can also regulate malignant
brain tumor growth involving several mechanisms, ranging from
activity-dependent release of growth factors to tonic release of
neurotrophins and neurotransmitters6,7.
In contrast, these stromal dependencies are likely to be greater
in benign tumors with fewer genetic mutations, such as those
arising in the setting of cancer predisposition syndromes, like
neurofibromatosis type 1 (NF1), in which affected patients
develop low-grade peripheral nerve sheath tumors and brain
tumors (optic pathway gliomas; OPGs). Whereas peripheral
nerve sheath tumors require growth factors from mast cells and
macrophages3,8, NF1-OPGs depend on resident brain monocytes
(microglia) for their formation and progression9,10. In Nf1
murine optic gliomas, microglial production of a key growth
factor (Ccl5) is both necessary and sufficient for tumor formation
and growth11,12. Importantly, microglial Ccl5 expression requires
T lymphocytes, such that glioma formation does not occur in
mice lacking functional T cells12. However, it is currently not
known how T cells are recruited to the developing tumor, how
they are activated, and how their activation results in microglia
Ccl5 production.
In light of the intimate association of these tumors with nerves
and the increasing recognition that neurons can provide
instructive signals to cancer cells, we sought to dissect the critical
tumor-promoting axis involving neurons, immune cells, and low-
grade gliomas (LGG) cancer cells using numerous converging
cellular and molecular methodologies. Herein, we describe the
complex cellular and molecular interactions between neurons,
T cells, microglia, and glioma cells that comprise the LGG eco-
system, revealing critical roles for neurons and T cells in glioma
formation and maintenance. We demonstrate that human and
mouse NF1-mutant neurons produce midkine to activate T cells,
which in turn leads to increased T cell Ccl4 secretion and the
priming of microglia to elaborate Ccl5 to maintain LGG cell
growth. Moreover, we identify each of the responsible intracel-
lular signaling pathways and show that inhibiting integrin-
mediated T cell brain entry or function is sufficient to attenuate
glioma growth in vivo. The discovery of this co-dependent neu-
ron/T cell/microglia/cancer cell axis provides opportunities for
future pediatric LGG therapeutic targeting.
Results
T cell Ccl4 induces microglial Ccl5 production. Previous studies
from our laboratory demonstrated that only activated, but not
naïve, T cells produce paracrine factors that induce microglia to
produce Ccl5 (Fig. 1a)10. To identify the paracrine factors
induced by T cell activation, we employed a commercially
available cytokine array to query the conditioned medium (CM)
from activated (anti-CD3/CD28-mediated activation) versus
naïve (non-activated) T cells in triplicate. In total, nine cytokines/
chemokines (i.e., TNFα, GM-CSF, Ccl2, Ccl1, Ccl3, Ccl4, Ccl5,
IL-1ra, and IL-2) were increased in activated, relative to non-
activated, T cell-CM (Fig. 1b and Supplementary Fig. 1a). We
tested the ability of these cytokines to induce microglial Ccl5
production. After validating the increased expression of these
nine cytokines, and the unaltered expression of two additional
cytokines (Il10 and Ifnγ) (Fig. 1c and Supplementary Fig. 1b) as
negative controls, we treated WT microglia with each cytokine at
the same concentrations measured in the activated T cell CM, and
determined the microglia Ccl5 expression levels by ELISA. Only
Ccl4 increased microglial Ccl5 protein expression to the levels
seen following activated T cell CM treatment in both adult and
neonatal microglia (Fig. 1a, d and Supplementary Fig. 1c, d).
Similar results were obtained using different concentrations of
these candidate cytokines (Supplementary Fig. 2a–h). While
microglia were the major cell type expressing Ccl5 in the murine
Nf1 optic gliomas (Supplementary Fig. 1e), activated T cells
produced some Ccl5 (Fig. 1a), which could contribute to the Ccl5
induction observed in our experimental paradigm. To exclude
T cell Ccl5 from the observed microglial response, activated
Ccl5−/− T cells were analyzed. Ccl5-deficient T cell CM elicited a
similar increase in microglial Ccl5 secretion, demonstrating that
the Ccl5 produced by T cells did not contribute in this setting
(Supplementary Fig. 2i).
Using the Immgen database, Ccl4 expression is enriched in
several T cell populations, including regulatory T cells (Tregs)
and CD8+ T cells (Supplementary Fig. 2j). To determine whether
Ccl4 is necessary for T cell CM-induced microglial Ccl5
production, a combination of Ccl4-neutralizing antibodies and
Ccl4 receptor (Ccr5 and Ccr8) inhibitors were employed: Ccl4-
neutralizing antibodies reduced activated T cell-induced micro-
glia Ccl5 production by >60% (Fig. 1e). While both Ccr5 and
Ccr8 were expressed by microglia (Fig. 1f), neither inhibiting
Ccr5 (MCV treatment) or Ccr8 (AZ058 treatment) alone reduced
Ccl5 to the same level as Ccl4-neutralizing antibodies (Fig. 1g).
However, the combination of Ccr5 and Ccr8 inhibition (MCV+
AZ058) reduced activated T cell-induced microglia Ccl5 produc-
tion by ~60%, comparable to the effect observed with Ccl4-
neutralizing antibodies (Fig. 1e, g). As controls, microglia were
exposed to non-activated T cell CM in the presence or absence of
Ccl4 receptor inhibition, with no effect on microglia Ccl5
production (Supplementary Fig. 2k). Since Ccl5 inhibits the
apoptosis of Nf1-deficient high-grade glioma cells13, we analyzed
the biological consequence of each of these reductions in Ccl5
expression on optic glioma stem cell (o-GSC) survival. Decreasing
Ccl5 concentrations from 700 pg ml−1 to 400 or 200 pg ml−1,
representing the Ccl5-inhibitory effect from anti-Ccl4 and Ccr5/
Ccr8 blockers, increased o-GSC apoptosis by 50% or to untreated
baseline levels, respectively (Supplementary Fig. 2l), thus estab-
lishing a clear biological effect of this Ccl4 axis inhibition on
microglial support of LGG stem cell survival.
Ccl3 also increased microglia Ccl5 production, albeit to a far
lesser extent (2.5-fold increase vs.18.5-fold increase in response to
Ccl4; Fig. 1d). However, the combination of Ccl3 and Ccl4
together did not further increase microglial Ccl5 expression
beyond what was seen with Ccl4 alone (Supplementary Fig. 2m).
Taken together, these results establish Ccl4 as the cytokine
responsible for inducing microglia Ccl5 production relevant to
glioma growth regulation.
MDK from NF1-mutant neurons induces T cell Ccl4 produc-
tion. Since our experimental paradigm involved a non-physiologic
method of T cell activation, we next sought to identify the factor(s)
responsible for NF1-mediated T cell activation in the setting of
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Nf1 OPG. For these studies, we leveraged both human-induced
pluripotent stem cells (hiPSCs) harboring actual NF1 patient
germline NF1 gene mutations, as well as Nf1-mutant mice.
Human neurons were generated from isogenic hiPSCs either
heterozygous (NF1-het) or homozygous (NF1-null) for two NF1
patient germline NF1 gene mutations [c.2041C>T and c.6576C>T]
using established protocols13. In light of previous work demon-
strating elevated midkine (MDK) levels in NF1 patient samples,
including low-grade peripheral nerve sheath tumors (neurofi-
bromas14) and skin15, we employed a commercial array contain-
ing MDK and other cytokines. Using this assay, NF1-null neurons
secreted higher levels of MDK and CSF-2 relative to control
neurons (Supplementary Fig. 3a). Quantitative real-time poly-
merase chain reaction (qRT-PCR) validation revealed increased
MDK, but not CSF2, mRNA expression in NF1-null, relative to
control, neurons (Supplementary Fig. 3b, c). In contrast, increased
CSF-2 protein levels were detected by ELISA in the CM of both
NF1-null neurons relative to control neurons, but at much lower
levels relative to MDK [CSF-2: 100–300 pgml−1 (Supplementary
Fig. 3d), MDK: 40,000–50,000 pgml−1 (Fig. 2a)].
Neuron-derived MDK or CSF-2 could influence T cell biology
in two ways. First, it could function as a chemoattractant for
T cells. However, CD3+ T cell migration measured using a
transwell assay was not increased in response either to MDK or
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CSF-2 (Fig. 2d; Supplementary Fig. 3e). Second, it is possible that
MDK or CSF-2 activates T cells to produce Ccl4. For these
experiments, we stimulated CD3+ T cells with either MDK or
CSF-2 at the concentrations measured in the CM of heterozygous
NF1-mutant hiPSC-derived neurons (~50 ng ml−1 MDK, 200 pg
ml−1, CSF-2), as seen in patients with NF1. While T cells
exhibited increased Ccl4 production in response to MDK
stimulation (Fig. 2e), there was no Ccl4 induction following
CSF-2 treatment (Supplementary Fig. 3f), thus excluding CSF-2
as a potent neuronal T cell activator.
To determine whether MDK mediates hiPSC-derived neuron
CM to increase T cell Ccl4 release, T cells were incubated with
CM collected from control and heterozygous NF1-mutant
(c.2041C>T and c.6576C>T) hiPSC-derived neurons. Treatment
with the CM of c.2041C>T and c.6576C>T NF1-mutant hiPSC-
neurons increased T cell Ccl4 production (Fig. 2f). MDK
mediated this induction, since MDK-neutralizing antibodies
attenuated the neuron CM-induced Ccl4 increase (Fig. 2f). It
should be noted that NF1-mutant neuron CM contains a similar
concentration of MDK (50 ng ml−1) to the commercially purified
MDK used for T cell treatment (Fig. 2e). The fact that
hiPSC NF1-mutant neuron CM was diluted in T cell CM (30%
v/v) in order to maintain healthy T cell cultures, reduced the
overall concentration of MDK by three-fold compared to the
purified MDK treatments, thus resulting in relatively attenuated
Ccl4 induction. Consistent with MDK as the primary activation
signal for T cell priming of microglia, CM from MDK-treated
T cells induced microglial Ccl5 production to an equivalent extent
after normalizing to cell number and medium volume (Fig. 2g).
Finally, we sought to define the mechanism underlying NF1
protein (neurofibromin) control of neuronal MDK expression. As
the main function of the NF1 protein is to negatively regulate
RAS activity, we treated control and NF1-mutant hiPSC-induced
neurons with lovastatin (a crude RAS inhibitor) at different
concentrations16. Following lovastatin treatment, MDK expres-
sion in these NF1-mutant hiPSC-induced neurons was reduced
(Supplementary Fig. 3g), without alterations in neuronal survival
(Supplementary Fig. 3h).
Relevant to human and mouse NF1-LGG, we also examined
MDK expression in the Nf1 OPG mice and human NF1-LGG
(pilocytic astrocytoma; PA) samples. Consistent with the
hiPSC NF1-mutant neuron findings (Fig. 2a), optic nerves from
Nf1+/− and Nf1 OPG mice exhibited higher levels of Mdk
transcript expression (Fig. 2b, c), and a greater percentage of
MDK-expressing cells in the retinal ganglion cell layer of the
retina relative to control mice (Fig. 2h). In addition, MDK
transcript expression was elevated in NF1-PA samples relative to
non-NF1-PA and normal brain tissue (Fig. 2i). Taken together,
these results establish increased MDK expression as a common
feature unique to mouse and human NF1-LGGs, not shared with
non-NF1-PAs, which functions as an activator of T cells to
produce Ccl4.
MDK induces T cell Ccl4 via Lrp1/calcineurin/NFAT1 signaling.
To determine how MDK activates T cells, we examined the
expression of its known receptors, including Ptprz117, Cspg518,
Lrp1, Lrp619, and Alk20. By qRT-PCR, T cells express abundant
Lrp1 (Fig. 3a). To determine whether Lrp1 was necessary for
MDK-mediated Ccl4 secretion from T cells, we incubated T cells
with MDK or hiPSC NF1-mutant neuron CM in the presence of
Lrp1-neutralizing antibodies. Lrp1-neutralizing antibodies
inhibited the ability of both MDK and hiPSC NF1-mutant neuron
CM to increase T cell Ccl4 expression (Fig. 3b,c). MDK has been
reported to signal through multiple different intracellular path-
ways involving Akt, Atf21, Stat4, NFAT1, NFAT222, and Src23.
While no differences in Akt, Atf, Stat4, NFAT2 activation were
observed (Supplementary Fig. 4), increased nuclear NFAT1 levels
were detected following MDK exposure (Fig. 3d). This nuclear
translocation results from dephosphorylation of the serine-rich
region (Serine-54) within the amino termini of NFAT1 proteins,
and the following conformational change that exposes a nuclear
localization signal24. As such, MDK treatment also depho-
sphorylated NFAT1 (Fig. 3e). Importantly, Lrp1 inhibition
increased phosphorylated NFAT1S54 levels and blocked the
nuclear translocation of NFAT1 in the setting of MDK exposure
(Fig. 3e). Lrp1 can activate NFAT1 through ERK and calci-
neurin25. While we observed no change in ERK activity after
MDK exposure (Supplementary Fig. 4), NFAT1 nuclear transport
was reduced following calcineurin inhibition26 (FK506; Fig. 3f).
Fig. 1 Activated T cells secrete Ccl4 and prime microglia to produce Ccl5. a Activated T cell conditioned medium (act-Tm CM) treatment stimulated WT
microglia (MG) to produce a higher level of Ccl5 (ELISA) compared to non-activated T cell-conditioned medium (non-act-Tm CM). Non-activated and
activated T cell CM, and CM collected from microglia alone served as controls for these experiments. b WT T cells isolated from the mouse spleen were
seeded at the concentration of 2.5 × 106 cells ml−1 in complete PRIM1640 medium followed by 2 days of CD3/CD28 stimulation (activated; act-Tm) or
vehicle (PBS) treatment (non-activated; non-act-Tm). CM was collected for chemokine array triplicates. Increased levels of TNF-α, GM-CSF, Ccl2, Ccl1,
Ccl3, Ccl4, Ccl5, Il-1ra, and Il-2 expression were observed in activated T cell CM relative to non-activated T cell CM. The fold increases and P values relative
to control groups for all three replicates (Supplementary Fig. 1a) are collated in the table. c ELISA assays reveal increased levels of TNFα, GM-CSF, Ccl2,
Ccl1, Ccl3, Ccl4, Ccl5, Il-1ra, and Il-2 in the CM of activated, relative to non-activated, T cells. d WT microglia were stimulated with these differentially
expressed cytokines [TNF-α (400 pgml−1), GM-CSF (1000 pgml−1), Ccl2 (80 pgml−1), Ccl1 (500 pgml−1), Ccl3 (8000 pgml−1), Ccl4 (6000 pgml−1),
Il-1ra (80 pgml−1), and Il-2 (6000 pgml−1)] for 24 h at the concentrations detected in the activated T cell CM. Ccl5 production by microglia was increased
following Ccl4 (6000 pgml−1) treatment. Veh: vehicle. e Ccl5 ELISA revealed that activated T cell CM induction of microglial Ccl5 production was reduced
following treatment with increasing concentrations of Ccl4 neutralizing antibody. f Microglial Ccr5 and Ccr8 expression was validated using spleen as a
positive control. g Increasing concentrations of maraviroc (MCV, Ccr5 receptor inhibitor) and AZ084 (Ccr8 receptor inhibitor) reduced T cell induction of
microglial Ccl5 expression. The combination of MCV and AZ084 exhibited the greatest inhibition of microglial Ccl5 expression. All data are presented as
the mean ± SEM. a This representative experiment was conducted with n= 3 independent biological samples, and was replicated two additional times with
similar results. b n= 3 independent biological samples were examined over three independent experiments, as illustrated in Fig. S1a. c and d Bar graphs
represent the means ± SEM of n= 3 independent biological samples. e This representative experiment was conducted with 0mgml−1 anti-Ccl4, n= 6; 1, 2,
2.5 mgml−1 anti-Ccl4, n= 3, independent biological samples, and was replicated two additional times with similar results. f Bar graphs represent the
means ± SEM of n= 4 independent biological samples. g This representative experiment was conducted with (from left to right) n= 7, n= 6, n= 6, n= 4,
n= 5, n= 4, and n= 5 independent biological samples, and was replicated two additional times with similar results. a, d, e, g One-way ANOVA with
Bonferroni post-test correction; b, c, f Two-tailed Student’s t-test. Exact P values are indicated within each panel; N.S.; not significant. From left to right in
each panel: a all P < 0.001, c all P < 0.001, d N.S., N.S., N.S., N.S., P= 0.035, P < 0.001, N.S., N.S.; e P= 0.025, P < 0.001, P < 0.001; f N.S.; g P= 0.012, P <
0.001, P < 0.001, P < 0.001, P < 0.001, P < 0.001.
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Moreover, MDK-induced T cell Ccl4 production was reduced
following treatment with the FK506 and cyclosporin (calcineurin
inhibitors24; Fig. 3g). FK506 treatment also inhibited hiPSC-
derived neuron CM induction of T cell Ccl4 production (Fig. 3h).
Collectively, our findings demonstrate that MDK binds to Lrp1
on T cells and induces Ccl4 expression through calcineurin-
mediated NFAT1 nuclear translocation.
CD8+ T cell brain entry is required for optic glioma growth.
While the above studies revealed important roles for neurons and
T cells in LGG stroma-tumor circuitry, they do not establish
whether T cells are necessary for optic glioma growth. To
demonstrate a requirement for T cells and directed T cell infil-
tration in murine Nf1 optic glioma growth, we performed two
preclinical proof-of-principle experiments using neutralizing
antibodies. First, Nf1 OPG mice were treated with anti-CD3
antibodies to deplete T cells from 6 weeks of age until 3 months of
age, verified by flow cytometry of splenic cells (IgG group, 55%
CD3+ cells; anti-CD3 group, 7.61%; Fig. 4a). Relative to isotype
antibody (IgG) treatments, the OPGs in these mice had reduced
numbers of CD3+ T cells and attenuated tumor proliferation
(Fig. 4b). Second, since T cells are rarely found in the normal brain
parenchyma, but are detected in NF1-associated mouse and
human LGGs12,27, we examined the meningeal space in control
(CTL, Nf1flox/flox) and Nf1 optic glioma (OPG, Nf1flox/mut; GFAP-
Cre) mice as a potential point of entry28. Similar to the optic
nerves27, more CD3+ T cells were observed in the meningeal
space of OPG mice relative to controls (Fig. 4c), suggesting that
T cells in the setting of optic gliomas are most likely recruited
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from this location into the evolving tumor. Because T cell
migration from the meningeal space is mediated by integrins, such
as the very late antigen 4 (VLA4)29, Nf1 OPG mice were treated
with anti-VLA4 antibodies in a parallel experiment. Consistent
with a dependency on integrin for T cell parenchymal invasion,
anti-VLA4 treatment inhibited CD3+ T cell tumor infiltration,
and reduced tumor proliferation (Fig. 4b). Interestingly, neither
treatment affected microglia content (Iba1+ cells, Fig. 4b).
Next, we sought to determine which T cell population
predominated in these tumors using CD4, CD8, and Foxp3
antibodies. Whereas no Foxp3+ cells were detected in the OPGs
(Supplementary Fig. 5a), the majority of the T cells in the tumors
were CD8+ cells, rather than CD4+ cells (Fig. 5a). The cellular
identity of these CD8+ cells in the mouse Nf1 OPGs were verified
as CD3+ T cells by double labeling immunohistochemistry
(Fig. 5b). A similar pattern was also observed in the meninges of
these mice, where the vast majority of the T cells were CD8+,
with a smaller infiltration of CD4+ cells (Fig. 5c). Consistent with
these findings in murine OPGs, CD8+ T cells were also detected
in human NF1-PAs (N= 4; Supplementary Fig. 5b).
To establish a requirement for CD8+ cells in Nf1 OPG growth,
we employed anti-CD8 antibody treatment to deplete CD8+
T cells using a protocol similar to that described for the anti-CD3
treatments. CD8+ T cell depletion was validated in splenocytes by
FACS analysis (IgG group, 50.3% CD8+ cells; anti-CD3 group,
0.18%; Supplementary Fig. 5c). As observed following CD3
antibody exposure, the OPGs in treated mice had reduced
numbers of CD3+ T cells and attenuated tumor proliferation, but
no change in microglia content (Fig. 6a). Consistent with a key
role for this population of T lymphocytes in LGG pathobiology
and similar to CD3+ T cells, CD8+ T cells produced Ccl4 in
response to MDK (Supplementary Fig. 5d), which was inhibited
by MDK-neutralizing antibodies (Supplementary Fig. 5d). Addi-
tionally, microglia exposed to MDK-treated CD8+ T cell CM
exhibited similar levels of microglial Ccl5 (Supplementary Fig. 5e)
as observed following MDK-treated CD3+ T cell CM exposure
(Fig. 2g). Consistent with the T cell Ccl4 regulation of microglial
Ccl5 expression, anti-CD8 antibody treatment of Nf1 OPG mice
reduced the percent of Ccl4+and Ccl5+cells in the murine LGGs
(Fig. 6a).
Lastly, to explore the possible clinical relevance of CD8+ T cell
infiltration, we analyzed CD8 and CD4 RNA expression in
datasets with LGG [Brain Lower Grade Glioma (TCGA,
Provisional, overlapping patients excluded) and Brain Lower
Grade Glioma (TCGA, PanCancer Atlas) samples]30. In both
LGG datasets, shorter overall survival correlated with increased
CD8, but not CD4, expression (Fig. 6b, c). Similarly, increased
CD8 expression also correlated with reduced progression-free
survival in the one dataset (TCGA, Provisional) with sufficient
numbers of samples for analysis (Supplementary Fig. 5f). Taken
together, these findings demonstrate that CD8+ T cell entry into
the brain is required for Nf1 OPG growth, which is also associated
with poor clinical outcome in patients with LGG.
T cell-induced microglial Ccl5 production inhibits apoptosis.
Additionally, we sought to elucidate the mechanisms responsible
for microglia Ccl5 production and LGG cancer cell growth. Initial
experiments focused on defining the monocyte population
(macrophages versus microglia) and the effect of a germline Nf1
gene mutation on the involved monocyte population. First,
while the monocytes that populate the murine Nf1 OPGs are
CD11b+/CD45low/Cx3cr1+ cells (microglia)9, rather than per-
ipheral CD11b+/CD45high/Cx3cr1- macrophages, we nevertheless
examined the responses of WT splenic monocytes (macrophages)
to activated T cell CM (Supplementary Fig. 6a). In striking con-
trast to the results obtained with microglia, no significant
induction of Ccl5 in splenic monocytes was observed, supporting
a T cell-microglia, rather than T cell-macrophage, circuit in the
maintenance of Nf1 OPGs. Second, because the stromal (T cells
and microglia) cells in both murine and human NF1-OPG are
heterozygous for a germline NF1 gene mutation, we also exam-
ined the ability of Nf1+/− T cells and microglia to interact and
produce Ccl5. Similar induction of microglial Ccl5 was observed
using activated Nf1+/− T cell CM or Nf1+/− microglia (Supple-
mentary Fig. 6b, c). For these reasons, we explored the regulation
of Ccl5 using WT T cells and microglia.
Since NFκB has been previously implicated in Ccl5 transcrip-
tional regulation31, we examined NFkB inhibitor (Iκbα) phos-
phorylation in microglia following exposure to activated T cell
CM. Increased Ikbα phosphorylation, indicating higher levels of
NFκb activity, was observed following activated T cell CM
treatment, which was abrogated using an NFκB inhibitor (Caffeic
acid phenethyl ester, CAPE) (Fig. 7a). Importantly, increased
Fig. 2 NF1-mutant neurons express MDK, which activates T cells to produce Ccl4. a Isogenic hiPSC-induced neurons with heterozygous NF1 patient NF1
gene mutations (2041C>T and 6576C>T) produced higher levels of midkine in the neuron conditioned medium (N-CM) compared to WT (CTL) hiPSC-
induced neurons. b Mdk gene expression was higher in the optic nerves of Nf1+/− relative to WT mice. c Increased Mdk expression was observed in optic
glioma (OPG)-containing relative to control (CTL) optic nerves. d No change in T cell migration was observed in response to various MDK concentrations.
eMDK (50 ngml−1) stimulation for 48 h increased T cell Ccl4 production. f CM from isogenic hiPSC-induced neurons with NF1 patient NF1 gene mutations
(c.2041C>T-N-CM and c.6576C>T-N-CM) exhibited a stronger T cell Ccl4 induction compared to CM from control hiPSC-induced neurons (CTL-N-CM).
Anti-MDK neutralizing antibodies reduced T cell Ccl4 production in response to hiPSC-induced neuron CM stimulation. g MDK-activated (50 ngml−1)
T cell CM (mid-treated Tm) increased microglial Ccl5 production relative to non-activated T cell CM (non-act-Tm). h Immunohistochemistry revealed an
increased percentage of MDK-immunoreactive cells in the retinal ganglion cell layer of OPG-bearing and Nf1+/− mice relative to control (CTL) or WT mice,
respectively. Scale bars, 40 µm. Arrows denote representative immunopositive cells. i MDK gene expression was examined in NF1 pilocytic astrocytomas
(NF1-PAs, n= 9), non-NF1-PAs (n= 9), and non-neoplastic brain tissues (n= 4). IncreasedMDK expression was detected in NF1-PAs compared to normal
brain tissue and non-NF1-PAs. Arrows denote representative immunopositive cells. All data are presented as the mean ± SEM. a–c These representative
experiments were conducted with a CTL, n= 3, 2041C>T n= 4, 6576C>T, n= 3; bWT, n= 7, Nf1±, n= 6; c CTL, n= 5, OPG, n= 4, independent biological
samples, and were replicated two additional times with similar results. d and e Bar graphs represent the means ± SEM of d n= 5, e n= 3, independent
biological samples. f This representative experiment was conducted with (from left to right) n= 3, n= 3, n= 3, n= 4, n= 3, n= 5, and n= 3 independent
biological samples, and were replicated two additional times with similar results. g Bar graphs represent the means ± SEM of non-activated Tm, n= 3;
MDK-treated Tm, n= 4 independent biological samples. h Bar graphs represent the means ± SEM of WT n= 9, Nf1+/−, n= 7, CTL, n= 5, OPG, n= 7,
independent biological samples. i Bar graphs represent the means ± SEM of CTL, n= 4, non-NF1, PA, n= 9, NF1, PA, n= 9, independent biological samples.
a, d, f, i One-way ANOVA with Bonferroni post-test correction, b, c, h Two-tailed Student’s t-test. Exact P values are indicated within each panel; N.S.; not
significant. From left to right in each panel: a all P < 0.00, 1 b P= 0.008, c P= 0.021, d all N.S.; f top P= 0.012, middle P= 0.023, P= 0.030, bottom P=
0.045, P= 0.039; i CTL:NF1 PA P= 0.024, non-NF1 PA:NF1-PA P= 0.007; h all P < 0.001.
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Fig. 3 MDK activates T cells to produce Ccl4 through Lrp1/calcineurin/NFAT1 signaling. a T cells expressed only two (Lrp1 and Lrp6) of the putative
MDK receptors [protein-tyrosine phosphatase ζ (Ptprz1), neuroglycan-C (Cspg5), low density-lipoprotein receptor-related protein-1 (Lrp1), low density-
lipoprotein receptor-related protein-6 (Lrp6) and anaplastic lymphoma kinase (Alk)] by quantitative RT-PCR. Normal mouse cortex was used as an internal
positive control. b Lrp1 blocking antibodies (30 µg ml−1) reduced MDK-induced Ccl4 production in T cells. c The 2041C>T neuron conditioned media (N-
CM)-mediated Ccl4 production in T cells was attenuated following exposure to Lrp1 receptor blocking antibodies. d Immunoblotting revealed increased
NFAT1 nuclear localization in T cells following MDK treatment. Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) and TATA-binding protein (TBP)
served as loading controls for the cytoplasm and nuclear fractions, respectively. e Decreased levels of phosphorylated-NFAT1 (p-NFAT) were observed
after MDK stimulation of T cells. Lrp1 blocking antibodies (anti-Lrp1, 30 µg ml−1) increased NFAT1 phosphorylation and impaired NFAT1 nuclear
localization in MDK-stimulated T cells. f The calcineurin inhibitor FK506 (10 μM) inhibited MDK-induced NFAT1 nuclear localization. g Calcineurin
inhibitors, cyclosporin (100 nM) and FK506 (10 μM), inhibited MDK-induced Ccl4 production in T cells. h FK506 (10 μM) reduced 2041C>T neuron
conditioned media (N-CM)-induced Ccl4 production in T cells. All data are presented as the mean ± SEM. a Bar graphs represent the means ± SEM of n= 3
independent biological samples. b, c; g, h These representative experiments were conducted with n= 3 independent biological samples,and were replicated
two additional times with similar results. b, c, g One-way ANOVA with Bonferroni post-test correction, h Two-tailed Student’s t-test. Exact P values are
indicated within each panel; N.S.; not significant. From left to right in each panel: b P= 0.005, P= 0.007; c N.S., P= 0.007; g P < 0.001, N.S., N.S.; h P <
0.001. d–f These are representative images of n= 3 independent biological samples examined over three independent experiments with similar results.
Molecular weight markers are denoted at the left side of each blot.
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microglial Ccl5 production in response to activated T cell CM
exposure was blocked by NFκB inhibition (CAPE; Fig. 7b).
Based on prior studies demonstrating that Ccl5 is necessary for
murine Nf1 OPG growth in vivo11,12 and operates to control
glioblastoma cell growth by inhibiting apoptosis, we next sought
to determine whether Ccl5 increases the survival of cancer stem
cells from murine Nf1 optic gliomas (optic glioma stem cells; o-
GSCs). We focused on these cells, since they are capable of
generating glioma-like lesions in mice following transplantation,
and no suitable primary human NF1-LGG cell lines are currently
available for analysis. Whereas Ccl5 treatment in the growth
phase (non-confluent) did not change the percentage of
proliferating (Ki67+) o-GSCs (Fig. 7c), Ccl5 reduced the
apoptosis of confluent o-GSC cultures (TUNEL staining; Fig. 7d).
To identify the signaling pathway underlying Ccl5 control of o-
GSC apoptosis, we performed a survey of known NF1 protein
(neurofibromin) downstream effectors. While no change in ERK
activity was observed following Ccl5 treatment (Supplementary
Fig. 6d), Akt and CREB phosphorylation was increased (Fig. 7e).
Since Akt activates the CREB pathway through GSK3β in
hepatocytes32, we measured GSK3β activity. Consistent with
Akt/GSK3β/CREB hyperactivation as the responsible pathway
underlying Ccl5-mediated o-GSC survival, Akt inhibition
(MK2206) following Ccl5 treatment attenuated Akt, GSK3β,
and CREB activation (using phospho-specific antibodies), as well
as increased o-GSC apoptosis (TUNEL) (Fig. 7e, f).
We have previously shown that CD44 is the CCL5 receptor on
Nf1-deficient high-grade glioma cells33. To determine whether
Ccl5 functions through this receptor, we first analyzed o-GSC
CD44 mRNA and protein expression (Fig. 7g,h). Second,
following Cd44 knockdown in o-GSCs, Ccl5 no longer inhibited
o-GSC death (Fig. 7h–j). As such, Ccl5 operates to increase low-
grade and high-grade glioma survival through CD44 binding and
downstream signaling.
Since Ccl5 mediates o-GSC survival via the AKT/GSK3β/CREB
pathway, we examined the percentage of p-AKTSer473-immuno-
positive cells and p-CREBSer133-immunopositive cells following
anti-CD8 treatment in Nf1 optic glioma mice. Consistent with T
cell Ccl4 induction of microglial Ccl5-mediated optic glioma
growth, we observed a reduction in the percentage of p-
AKTSer473-immunopositive cells and p-CREBSer133-immunopo-
sitive cells in the optic gliomas of anti-CD8 antibody-treated mice
(Fig. 8a, b).
Finally, in keeping with a key role for Ccl5 and CD44 in LGG,
high CCL5 or CD44 expression also correlated with reduced
overall survival in the two available TCGA datasets with LGGs
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(overlapping patients excluded; Fig. 8c, d). A similar correlation
between high tumor CCL5 expression and reduced progression-
free survival was observed in the one dataset with sufficient
numbers of samples for analysis; Supplementary Fig. 6e).
Discussion
Using NF1 as a genetic model system to study low-grade brain
tumor pathobiology, we found that the glioma microenvironment
is composed of immune (T cells and microglia) and non-immune
(neurons) stromal cells, which together establish fertile soil sup-
portive of the development and progression of these tumors. In
this regard, we show that CD8+ T cells are required for glioma
growth, such that inhibiting their entry into the brain attenuates
tumor proliferation (VLA4, CD3, and CD8 antibody treatments).
Moreover, we demonstrate that NF1-mutant neurons support
glioma growth by producing MDK, which activates T cells to
produce Ccl4, a cytokine that induces microglia to express a
critical glioma growth factor (Ccl5) (Fig. 8e). These findings raise
several important points relevant to solid tumor pathobiology.
While traditionally viewed as bystander cells in the pathogen-
esis of cancer, recent studies argue that neurons provide instruc-
tive cues for tumor formation and growth. First, neurons secrete
neurotransmitters and neuropeptides, which can bind to their
cognate receptors on tumor cells to directly increase brain tumor
cell growth34. Second, using optogenetic approaches, increased
neuronal activity has been shown to drive high-grade glioma
growth through the shedding of neuroligin-3, a protein normally
involved in neuron–neuron communication6. Third, nerve
innervation is a poor prognostic marker in many cancers outside
of the nervous system (pancreas and prostate cancer)35,36 such
that neuron-secreted factors promote tumor initiation, growth,
and metastasis37,38. For example, autonomic nerve fibers posi-
tively mediate prostate cancer initiation and progression through
adrenergic and cholinergic signaling pathways37. In addition,
neural progenitor cells (NPCs) can migrate from the brain to
prostate tumors, and drive tumor proliferation and metastasis39.
In addition to directly mediate tumor growth, neurons can also
contribute to tumorigenesis by modulating immune cell function.
In the brain, neurons produce membrane-bound and soluble
factors (e.g., CD2240, CD20041, ICAM-542, semaphorin-3A43,
and CX3CL144) that each can modulate microglia properties.
These tightly regulated interactions are not only essential for
normal brain development, during which neuronal complement
(C1q) expression triggers microglia-mediated synaptic pruning,
but can be subverted to drive nervous system disease progression
in the setting of peripheral nerve injury45 and neurodegenerative
disorders46. Similarly, neurons produce TGFβ to increase CD4+
T cell proliferation47, as well as Fas ligand to promote T cell
apoptosis48.
Our finding that NF1-mutant mouse and human neurons
increase their expression of MDK, which operates to activate
T cells through NFAT-1 signaling, also expands the role of
neurons as immune system regulators. In this regard, neuronal
shedding of intercellular adhesion molecule (ICAM)-5 inhibits
the activation of naïve T cells49. While further studies will be
required to understand how neuronal MDK is regulated relative
to glioma growth, MDK has been previously implicated in the
suppression of regulatory T cell (Treg) expansion50, as well as in
the growth of experimental neurofibromas arising in the context
of NF114,51. While MDK activation of T cells is the operative
mechanism underlying NF1-LGG pathogenesis, other etiologies
are likely responsible for non-NF1 (sporadic) LGG initiation and
growth. As such, elevated MDK expression was not observed in
non-NF1 PA samples relative to normal brain tissue (Fig. 2i), and
MDK expression is not correlated with LGG patient survival
using available TCGA data (Supplementary Fig. 6f).
T cells normally provide a level of immune surveillance by
trafficking from the cerebrospinal fluid through the brain, and
draining back into the periphery via lymphatic vessels in the
meningeal spaces52. Although not present in large numbers in the
healthy brain, the amount of infiltrating T cells is increased in
numerous different histologic brain tumor subtypes, each of
which displays a unique pattern of immune cell infiltration and
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Fig. 5 Nf1 optic glioma mice exhibit increased numbers of CD8+ T cells in the meninges and optic nerve. a Increased CD3+ and CD8+ T cell infiltration
was observed in Nf1 optic glioma (OPG)-containing nerves relative to control (CTL) optic nerves. Few CD4+ T cells were detected in murine Nf1 OPG or
control optic nerves. Black arrows denote representative immunopositive cells. Scale bars, 20 µm. b CD3+ (red); CD8+ (green) double-positive cells were
found (yellow arrow) in murine Nf1 optic gliomas. c Increased numbers of meningeal CD4+ and CD8+ T cells (green) were present in Nf1 OPG mice
relative to controls, where the number of CD8+ T cells was three-fold higher than CD4+ T cells. DAPI (blue) is used as a nuclear counter stain. Yellow
arrows denote representative immunopositive cells. b, c Scale bars, 40 µm. a, c Bar graphs represent the means ± SEM of a (left panel) n= 6, (middle
panel) CTL, n= 5; OPG, n= 6, (right panel) n= 5 or c n= 6 independent biological samples. a Two-tailed Student’s t-test, c One-way ANOVA with
Bonferroni post-test correction. Exact P values are indicated within each panel; N.S.; not significant. From left to right in each panel: a left panel P= 0.006,
middle panel N.S., right panel P= 0.007; c P= 0.004, P < 0.001.
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transcriptional signatures53,54. However, the contribution of CD4+
and CD8+ T cells to these tumors remains unclear. For example,
pediatric LGG exhibit higher levels of T cell infiltration relative to
their malignant counterparts55, while CD4+ and Foxp3+ T cell
glioma content correlated with increased tumor progression56.
Similarly, infiltrating T cells correlated with poor patient survival
in one study57, whereas another demonstrated that CD8+ T cell
content is associated with improved patient survival58.
Herein, we found that the majority of T cells in these low-grade
murine gliomas are CD8+ lymphocytes, such that their depletion
attenuated OPG growth in vivo. While these T cells are typically
considered cytotoxic in nature, it is possible that they represent a
population of exhausted T cells, which could be converted to
tumoricidal59. Future experiments will be necessary to define
their unique functional properties in this particular neoplastic
setting. Similarly, whereas VLA-4 is required for CD8+ T cell
infiltration into Nf1 optic gliomas, as revealed by the anti-VLA4
antibody experiments, differential VLA-4 expression in CD4+
versus CD8+ T cells does not account for the preferential CD8+
T cell infiltration in Nf1 murine optic gliomas28 and human
NF154 gliomas (Supplementary Fig. 6g, h). However, since T cells
are recruited into murine Nf1 optic gliomas by chemokines (Ccl2
and Ccl12) released by o-GSCs27, it is possible that differences in
T cell population recruitment may result from differential
responses to these chemokines. Future studies are focused on
mechanistically defining how CD8+ T cells are selectively
recruited into these LGGs27,60.
As systemic immune regulators, T cells have the capability to
educate macrophages/microglia in both health and disease28,61. In
other brain diseases, infiltrating T cells are in close vicinity to
influence microglia/macrophages62. In addition, T cells suppress
microglia activation in the phase of inflammatory insults, as well
as produce cytokines (e.g., IL-4) that can alter microglia func-
tion63. Similarly, in many types of cancer, T cells interact with
tumor-associated microglia/macrophages (TAMs) through the
secretion of factors, like IL-4 and IL-1364 and alter tumor growth
or invasion. This connection is underscored by previous work
from our laboratory in which microglia from athymic (nu/nu)
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Fig. 6 CD8+ T cells control Nf1 optic glioma growth. a Immunohistochemistry revealed that anti-CD8 antibody treatment reduced the number of CD3+
T cells, as well as the percentage of Ki67+ cells, Ccl4+ cells, and Ccl5+ cells, in Nf1 optic glioma specimens. Black arrows denote representative
immunopositive cells. Scale bar, 40 µm. No differences in microglia (%Iba1+ cells) content were observed in anti-CD8 treated mice compared to the IgG
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LGG and high tumor CD8 expression have shorter survival time, while c high CD4 expression was not associated with reduced survival time (Brain Lower
Grade Glioma TCGA Provisional [left panel; P= 0.371] and TCGA PanCancer Atlas [right panel; P= 0.598] datasets).
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mice exhibit reduced phagocytosis and reduced Ccl5 expres-
sion12. Consistent with T cell-mediated microglia education,
incubating nu/nu mouse brain microglia with activated wild-type
(WT) T cells or their CM resulted in restoration of normal Ccl5
levels. The ability of T cells to communicate with microglia to
change their physiologic state and functional capabilities provides
another mechanism to control brain homeostasis and influence
CNS pathobiology. In light of the patient survival curves stratified
by CD8 and CCL5 tumor expression (Figs. 6b, 8c, d), these T
cell–microglia interactions may be particularly relevant to LGGs,
where MDK/CCL4-independent mechanisms involving CD8+
T cells and microglia result in CCL5 support of tumor growth.
Additional experiments using other LGG models will be required
to extend these findings beyond NF1.
In summary, the neuron–immune–cancer axis elucidated in
this study highlights the tightly choreographed interactions
between neoplastic cells and their non-neoplastic neighbors
(neurons, T cells, and microglia; Fig. 6h). Similar to other con-
texts in which numerous cell types (microglia, reactive astrocytes,
and oligodendrocyte precursor cells) interact to impact on brain
function (methotrexate-induced cognitive impairment65), the
findings in this report expand the concept of the tumor micro-
environment and the complex relationships between participating
cell types, including neurons, but also offer opportunities to target
the tumor ecosystem.
Methods
Mice. All mice, including Nf1+/− mice (neomycin sequence insertion within exon
31 of the murine Nf1 gene), Nf1flox/mut; GFAP-Cre (OPG) mice (Nf1+/− mice with
somatic Nf1 gene inactivation in neuroglial progenitors at E15.5) and Nf1flox/flox
mice (controls)66,67, were maintained on a strict C57BL/6 background and used in
accordance with an approved Animal Studies Committee protocol at Washington
University. Ccl5−/− mice were purchased from the Jackson Laboratory (JAX;
005090). Mice were housed in barrier facilities with controlled light–dark cycles
(12:12 h) and ad libitum access to food and water.
Anti-VLA4, anti-CD3, and anti-CD8 treatments. Six-week-old OPG mice (n=
10/cohort) were injected with 150 µg of anti-VLA4 (IgG2b), anti-CD3 (IgG2b),
anti-CD8 (IgG2b), or rat IgG (isotype control, Bio X Cell) intraperitoneally every
other day for 6 weeks. The brains and optic nerves were harvested when the mice
reached 3 months of age, and the Iba1, Ki67, and CD3-positive cells analyzed by
counting the number of cells showing a positive signal after
immunohistochemistry27.
Culture of mouse optic glioma stem cells, human iPSCs, and neurons. Optic
nerves/chiasms were dissected from 3-month-old Nf1 OPG mice and used to
generate o-GSCs68. Single cell suspensions were obtained by digesting the optic
nerve/chiasm in Trypsin Digest Medium, followed by maintenance in neural stem
cell (NSC) medium (61% DMEM low glucose medium, 35% neurobasal medium,
e
Veh Ccl5
Ccl5 +
MK2206
a
– + +
– – +
f
Ctrl
Veh Ccl5 Veh Ccl5
h
j
N.S.
b
)l
m/ gp(
5l c
C
+ +
– +CAPE:
i
g
- 37k
- 37k
- 50k
-75k
-37k
act-Tm:
c d
0
200
400
600
800
p = 0.001
Veh Ccl5
0
10
20
30
40
50
%
K
i6
7+
 c
el
ls
Veh Ccl5
0.0
0.5
1.0
1.5
R
el
at
iv
e
ap
op
to
si
s
p = 0.003
Veh Ccl5 Ccl5+
MK2206
0.0
0.5
1.0
1.5
p = 0.003
N.S.
R
el
at
iv
e
ap
op
to
si
s
0.0
0.5
1.0
1.5
C
d4
4 
ex
pr
es
si
on
Spleen o-GSC
0.8
0.9
1.0
1.1
1.2
R
el
at
iv
e
ap
op
to
si
s
Veh Ccl5
p = 0.119
CAPE:
act-Tm:
-50k
-50k
-50k
-50k
-50k
-50k
-37k
-37k
-75k
p-IκbαSer32
α-tubulin
Iκbα
α-tubulin
α- tubulin
CREB
CREB
p-CREBSer133
p-CREBSer133
p-GSK3βSer9
p-GSK3βSer9GSK3β
GSK3β
p-AktSer473
p-AktSer473
Akt
Akt
CD44
Ctrl o-GSCs CD44KD o-GSCs
CD44KD
GAPDH
CD44
-50k
-50k
-37k
-37k
Fig. 7 T cell-mediated microglial Ccl5 production inhibits LGG apoptosis through CD44. a Activated T cell CM (act-Tm) increased Iκbα phosphorylation
in microglia, which was reduced following Caffeic acid phenethyl ester (CAPE; 100 µM) treatment. b CAPE treatment attenuated activated T cell CM (act-
Tm)-mediated Ccl5 production in microglia. OPG o-GSCs were stimulated with Ccl5 at 300 pgml−1 for 3 days. Whereas no increased optic glioma stem
cell (o-GSC) proliferation (%Ki67+ cells) was observed c, o-GSC apoptosis (%TUNEL+ cells) was reduced in the Ccl5-treated group compared to vehicle
(Veh, 0.1% BSA) treated controls d. e Immunoblotting reveals activation of the Akt-GSK3β-CREB anti-apoptosis pathway following Ccl5 treatment, which
was inhibited by AKT inhibitor (20 μMMK2206) treatment. f 20 μMMK2206 treatment inhibited the anti-apoptosis effect of Ccl5 on o-GSCs (%TUNEL+
cells). g Cd44 expression in o-GSCs was detected by qRT-PCR using splenocytes as a positive control. Cd44 expression differences were not statistically
analyzed. h CD44 knockdown (CD44KD) in o-GSCs reduces CD44 expression relative to the control shRNA-treated (Ctrl) cells. i Apoptosis (%TUNEL+
cells) of CD44KD o-GSCs was not inhibited by Ccl5 treatment. j Immunoblotting reveals that Ccl5 activation of the Akt/GSK3β/CREB anti-apoptosis
pathway was inhibited by CD44 knockdown. All data are presented as the mean ± SEM. b–d, f, i These representative experiments were conducted with b
n= 3, c n= 6, d n= 5; f, i n= 4 independent biological samples and were replicated two additional times with similar results. g Bar graphs represent the
means ± SEM of n= 3 independent biological samples. b–d, i Two-tailed Student’s t-test; f One-way ANOVA with Bonferroni post-test correction. Exact
P values are indicated within each panel; N.S.; not significant. From left to right in each panel: b P= 0.001; c N.S.; d P= 0.003; f P= 0.003, N.S.; i P= 0.119.
a, e, h, j These are representative images of n= 3 independent biological samples examined over three independent experiments with similar results.
Molecular weight markers are denoted at the right side of each blot.
NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-020-15770-3 ARTICLE
NATURE COMMUNICATIONS |         (2020) 11:2177 | https://doi.org/10.1038/s41467-020-15770-3 |www.nature.com/naturecommunications 11
e
p-AKTSer473
Anti-CD8IgG IgGa b
100
80
60
40
20
0
20 60 100 140 180 220
100
80
60
40
20
0
c
20 60 100 140 180 220
CCL5 high
CCL5 low
20 60 100 140 180 220
CD44 high
CD44 low
20 60 100 140 180 220
d CD44 high
CD44 low
CCL5 high
CCL5 low
p = 0.002
IgG
%
p-
C
R
E
B
+
 c
el
ls 60
40
20
0
Anti-CD8
Anti-CD8
%
 p
at
ie
nt
s
Months
%
 p
at
ie
nt
s
100
80
60
40
20
0
%
 p
at
ie
nt
s
100
80
60
40
20
0
%
 p
at
ie
nt
s
Months Months Months
0
5
10
15
20
%
p-
A
K
T
+
 c
el
ls
IgG Anti-CD8
p < 0.001
CCL5
Akt
GSK3β
CREB
Cellsurvival
CD44
CCR5
CCL4
NFκB
CCL5
LRP1
MDK Calcineurin
NFAT1
CCL4Microglia
Glioma
cells
CD8+
T cells
Optic nerve/glioma
Midkine
NF1-mutant
RGC axon
MidkineRAS
NF1
Midkine
Meningeal space
CD8+
T cells
VLA4
CCL4
CCL5
Fig. 8 T cell-induced Ccl5/CD44-mediated cell survival underlies Nf1 optic glioma growth. a, b Immunohistochemistry revealed that anti-CD8 antibody
treatment reduced the percentage of p-AKTSer473-expressing and p-CREBSer133-expressing cells in mouse Nf1 optic glioma specimens. Black arrows denote
representative immunopositive cells. Scale bars, 20 µm. Bar graphs represent the means ± SEM of n= 4 independent biological samples. Two-tailed
Students-t test. Exact P values are indicated within each panel; a P < 0.001; b P= 0.002. c, d Kaplan–Meier survival curves (Brain Lower Grade Glioma
TCGA Provisional [2 left panels; c P= 1.29e−6, d P= 2.06e−3] and TCGA PanCancer Atlas [2 right panels; c P= 4.69e−13, d P= 9.86e−3] datasets)
demonstrate that non-overlapping patients with LGG who harbor high CCL5 expression or CD44 expression have reduced survival time. e Schematic
representation of the neuron–immune–cancer axis in NF1-LGG. Meningeal T cells infiltrate into the optic glioma in an integrin (VLA-4)-dependent manner,
and are activated by MDK produced by Nf1-mutant retinal ganglion cells (neurons) through a RAS-dependent mechanism. This neuron-mediated T cell
activation increases CD8+ T cell Ccl4 production through increased Lrp1/calcineurin signaling, and results in increased NFκB-dependent microglial Ccl5
expression, culminating in increased glioma growth through Akt/GSK3β/CREB pathway-mediated suppression of cancer (glioma) stem cell apoptosis and
increased tumor growth.
ARTICLE NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-020-15770-3
12 NATURE COMMUNICATIONS |         (2020) 11:2177 | https://doi.org/10.1038/s41467-020-15770-3 | www.nature.com/naturecommunications
2 mM L-glutamine, 1% penicillin/streptomycin; P/S) supplemented with Glutamax
(200 mM), EGF (20 ng ml−1), FGF (20 ng ml−1), 1% N2, and 2% B27.
Isogenic human iPSCs homozygous or heterozygous for the c.2041C>T or
c.6513T>A NF1 patient-specific NF1 germline mutations were engineered using
CRISPR/Cas9 technology by the Washington University Genome Engineering and
iPSC Core Facility (GEiC). NPCs were differentiated by passaging iPSCs onto PLO/
Laminin (Millipore Sigma)-coated plates using ReleSR (STEMCELL Technologies),
followed by seeding at 200,000 cells cm−2 in NPC induction medium [50% DMEM
F12 (Gibco), 50% Neurobasal medium (Gibco), supplemented with N2, B27
(Fisher), 2 mM GlutaMax (Gibco), 10 ng ml−1 hLIF, 4 µM CHIR99021, 3 µM
SB431541, and 0.1 µM Compound E (all from STEMCELL Technologies)]. NPCs
were maintained in this medium supplemented with 2 µM Dorsomorphin for
3 days, and without Dorsomorphin (STEMCELL technologies) for an additional
5 days. NPCs were subsequently incubated in NPC maturation medium (50%
DMEM/F12, 50% Neurobasal medium supplemented with N2, B27, 2 mM
GlutaMax, 10 ng ml−1 hLIF, 3 µM CHIR99021, and 2 µM SB431541), and were
passaged weekly following Accutase (STEMCELL Technologies) dissociation
according to manufacturer’s instructions. For differentiation into a mixed
population of CNS neurons, NPCs were plated on PLO/Laminin-coated plates in
Neuron Maturation Media (STEMCELL technologies) for 6 weeks prior to CM
collection. CM was then used for T cell stimulation, MDK ELISA (LifeSpan
Biosciences), CSF-2 (R&D Systems), and analysis using the Proteome Profiler
Human Cytokine Array (R&D Systems ARY017).The collected neurons were used
for mRNA isolation.
Human PA samples. The PA specimens used for qRT-PCR analyses were obtained
under an approved Human Studies Protocol as frozen tumor pellets from the St.
Louis Children’s Hospital Pediatric Tumor Bank, and included nine NF1 patient
PAs (3 males, 6 females; 10.11 ± 1.91 years), nine non-NF1 PAs (3 males, 6 females;
10.11 ± 1.76 years) and four non-neoplastic brain samples (2 males, 7 females;
10.25 ± 2.81 years). These de-identified specimens were used under an approved
protocol from the Washington University School of Medicine Institutional Review
Board. Human NF1-associated PA specimens used for immunohistochemistry
were obtained from Dr. Sonika Dahiya under an approved protocol at the
Washington University School of Medicine IRB. Immunohistochemistry was
performed on adjacent paraffin sections using the antibodies listed in Supple-
mentary Table 1. Detection was performed using the Vectastain Elite ABC kit
(Vector Laboratories, Burlingame).
Microglia/monocyte analyses. Each mouse brains were homogenized in the
gentle MACS™ Dissociator (Miltenyi) with 5 ml of digestion solution (116 mM
NaCl, 5.4 mM KCl, 26 mM NaHCO3, 1 mM NaH2PO4, 1.5 mM CaCl2, 1 mM
MgSO4, 0.5 mM EDTA, 25 mM glucose, 1 mM cysteine, and 20 units ml−1 papain)
for 30 min. 20 ml of PBS with 10% FBS was subsequently added to inactivate the
digestion solution. Next, the cells were centrifuged (200×g, 20 min) in 20% Percoll
overlaid with HBSS to remove the meninges. The cells were then treated with
DNase, centrifuged and passed through a 70 µm strainer. The resulting cells
maintained in minimal essential medium Earle’s medium supplemented with
1 mM L-glutamine, 1 mM sodium pyruvate, 0.6% D-(+)-glucose,1 ng ml−1 GM-
CSF, 100 μg ml−1 P/S, 4% FBS, and 6% horse serum.
After 2 weeks, microglia were separated from the astrocytes by shaking
(cultured in medium without GM-CSF 3 days before shaking, 200×g, 5 h, 37 °C).
5 × 105 microglia/monocytes were grown in T cell CM for 24 h12, and Ccl5
measured by an ELISA kit (R&D Systems). Maraviroc (MCV) (Fisher Scientific,
S2003), AZ0084 (MedChem Express, HY-119217) and Caffeic acid phenethyl ester
(CAPE) (Fisher Scientific, 274310) were purchased from Fisher Scientific. The
mouse recombinant cytokines [TNFα (Abcam, ab9740), GM-CSF (R&D Systems,
415ML101), Ccl2 (R&D Systems, 279-MC-010), Ccl1 (Fisher Scientific, EMCCL1),
Ccl3 (Novus Biologicals, NBP2-35193), Ccl4 (R&D Systems, 451-MB-010), Ccl5
(Fisher Scientific, 478MR025), IL-1ra (Novus Biologicals, NBP2-35105), and Il-2
(R&D Systems, 402-ML-020)] were added to microglia and the Ccl5 levels
quantified.
Optic glioma stem cell proliferation and apoptosis assays. To measure pro-
liferation, 104 o-GSCs were seeded, and the total cell number counted 3 days later.
To measure apoptosis, 105 o-GSCs were plated into 24-well plates coated with
poly-D-lysine (50 μg ml−1) and fibronectin (10 μg ml−1) in complete NSC medium.
After 3 days, cells were grown in NSC medium without N2, B27, FGF, and EGF for
48 h, fixed in 4% paraformaldehyde (PFA), and apoptosis quantitated using a
terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) kit
(Sigma-Aldrich). MK2206 (Fisher Scientific, S1078) was purchased from Fisher
Scientific.
T cell analyses. WT or Nf1+/− mouse spleens were homogenized into single cell
suspensions by digesting in PBS containing 0.1% BSA and 0.6% Na-citrate, washed,
and incubated with 120 Kunitz units of DNase I and red blood cell lysis buffer
(eBioscience, 00433357). CD3+ or CD8+ T cells were isolated by negative selection
using the pan-T-cell isolation kit II (Miltenyi Biotec, 130-095-130) or CD8a T Cell
isolation kit (Miltenyi Biotec, 130-104-075), respectively. T cells were maintained at
2.5 × 106 cells ml−1 in RPMI-1640 medium supplemented with 10% FBS and 1% P/
S. CM from activated (1.25 µg ml−1 anti-mouse CD3 [Fisher Scientific, 16-0031-
85] and 2 µg ml−1 anti-mouse CD28 [Fisher Scientific, 16-0281-82] antibody
treatment for 2 days) and non-activated T cells (no antibody exposure) were
collected, and the cytokines in the CM detected using the Proteome Profiler Mouse
Cytokine Array Kit (R&D Systems, ARY006). Anti-MDK neutralizing antibody
(Abcam, 170820) was used at a 1:50 dilution, while anti-Lrp1 blocking antibody
(Fisher, MA1-27198) was used at 30 µg ml−1. Cyclosporin (C3662) and FK-506
(F4679) were purchased from Sigma-Aldrich. Mouse splenic T cells were plated at
a density of 5 × 105 cells in 96-well plates and incubated with 200 µl medium
containing 30% iPSC-induced neuron CM and 70% complete RPMI-1640 (sup-
plemented with 10% FBS and 1% P/S).
To assay migration, 5 × 105 T cells were placed in the upper chamber of a
transwell chamber (Corning, 6.5 mm insert, 3.0 µm polycarbonate membrane,
CLS3398-2EA) with 200 µl serum-free PRIM 1640 media. 500 µl of
chemoattractant media (MDK or CSF-2, concentrations indicated in figures) was
added to the lower chamber, and the number of T cells in the lower chambers were
counted 4 h later.
Flow cytometry. Spleens from anti-CD3-treated mice were harvested when the
mice reached 3 months of age, and single-cell suspensions without red blood cells
were prepared from mouse spleens. Cells were incubated with anti-CD3PB anti-
bodies (BioLegend, 100431) at 4 °C for 30 min. Spleens from anti-CD8-treated
mice were harvested when the mice reached 3 months of age, and single-cell
suspensions without red blood cells were prepared from mouse spleens. Anti-CD4-
PerCP antibodies (BioLegend, 100431) and anti-CD8-APC antibodies (BioLegend,
100713) were added, and incubated with cells at 4 °C for 30 min. Flow cytometry
was performed using an Attune NxT Flow Cytometer (Thermo Fisher Scientific),
and analyzed using FlowJo v10.6.1 software.
Immunohistochemistry and immunofluorescence. Mice were euthanized and
perfused transcardially with Ringer’s solution, followed by 4% PFA, and the brains
and optic nerves/chiasms were processed for paraffin embedding and sectioning.
Immunohistochemistry was performed on adjacent paraffin sections with anti-
bodies listed in Supplementary Table 1. Detection was performed using the Vec-
tastain Elite ABC kit (Vector Laboratories, Burlingame). All sections were
photographed with a digital camera (Optronics) attached to an inverted micro-
scope (Nikon). For leptomeningeal analyses, 6-week old OPG and control mice
were perfused with Ringer’s solution, followed by PFA, and storage in 30% sucrose.
Floating sections of brains (20 µm-thick sections) were stained with anti-CD3/
CD4/CD8 antibodies for 1 h at 4 °C after 0.1% PBS-T (Triton X-100) treatment (5
min) and corresponding secondary antibodies (Alexa-fluor 488 for CD3 and 568
for CD4/CD8). DAPI was used for counterstaining during mounting.
Western blotting. Nuclear protein extracts were obtained using RIPA and protein
concentration was determined using the Pierce BCA protein assay kit. Up to 50 µg
of protein per extract were separated in SDS–polyacrylamide gels by electrophor-
esis. After protein transfer onto PVDF membrane, the membranes were incubated
with the indicated antibodies. Antibody binding was detected after incubation with
a secondary antibody coupled to IRDye. The blots were analyzed using Image
Studio Lite Ver 5.2 software. Images of the original immunoblots can be found in
Supplementary Figs. 8 and 9.
RNA extraction and real-time qRT–PCR. RNA was isolated from cells using the
RNeasy kit (QIAGEN), while RNA was isolated from mouse optic nerves using the
Trizol reagent (Life Technologies). Real-time qRT–PCR was performed using the
specific primers listed in Supplementary Table 2. ΔΔCT values were calculated
using H3f3a as an internal control.
Survival curves. Kaplan–Meier survival curves were obtained from the MSKCC
computational biology cancer genomics portal (http://www.cbioportal.org)30,69,
which contains two annotated TCGA datasets (Brain Lower Grade Glioma (TCGA,
Provisional) and Brain Lower Grade Glioma (TCGA, PanCancer Atlas). Statistical
significance was set at P < 0.05.
Lovastatin treatment. 100,000 human iPSC-derived NPCs were plated on PLO/
laminin-coated six-well plates, allowed to differentiate into neurons in neuron
maturation media for 6 weeks, and were then treated with varying concentrations
of lovastatin for 24 h. After an additional 12 h, the conditioned media was collected
for midkine ELISA measurements.
Primary neonatal microglia isolation and culture. Mouse pups (postnatal day
0–4; PN0–4) were euthanized, and their brains (without the cerebellum and
olfactory bulb) were collected and stripped of the overlying meninges. The brains
were then washed twice with ice-cold wash buffer and incubated with 3 ml of
trypsin (2.5%) at 37 °C for 20 min, followed by inactivating trypsin in 4 mls of
complete DMEM culture media (with 10% FBS). The cells were then treated with
DNase, resuspended in 10 mls of DMEM complete media, passed through a 70 µm
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strainer, and seeded in flasks. The culture media was changed on day 3, and cells
were fed with an additional 3 mls of fresh complete DMEM on day 7. Between days
8 and 14, microglia were isolated by shaking the flasks for 20–25 min at room
temperature on a shaker at 250 rpm.
Splenic monocyte isolation. For monocyte isolation, spleen single cell suspensions
were incubated with CD11b-specific magnetic beads, and captured using a mag-
netic separator. 5 × 105 microglia/monocytes were grown in T cell CM for 24 h1,
and Ccl5 measured by an ELISA kit (R&D Systems).
Statistical analyses. Data analyses were performed using GraphPad Prism.
Unpaired two-tailed Student’s t-tests were used to determine differences between
two groups. Multiple comparisons were analyzed by one-way analysis of variance
(ANOVA) with Dunnett’s multiple comparisons test. Statistical significance was set
at P < 0.05. All data are presented as mean values ± SEM. All experiments have
been replicated at least three independent times with similar results.
Data availability
The data are available within the Article, Supplementary Information and available from
the authors upon request. The source data for Figs. 1–8 and Supplementary Figs. 1–9 are
provided as a Source Data file. Additional data were extracted from the Memorial Sloan
Kettering Cancer Center cBioPortal for Cancer Genomics (https://www.cbioportal.org)
and the Immunological Genome Project (www.immgen.org).
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